Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218592

SCHEMBL23218592

SCHEMBL23218592

CCOC(=O)c1coc2c(CN(C)C)cc(Br)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 1/20 0.42
▸ GABRB1 P18505 1/20 0.42
▸ GABRA3 P34903 1/20 0.42
▸ GABRB2 P47870 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ MAOB P27338 2/20 0.40
▸ LMNA P02545 2/20 0.38
▸ MAPK1 P28482 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ CA12 O43570 2/20 0.37
▸ CA1 P00915 2/20 0.37
▸ CA2 P00918 2/20 0.37
▸ CA7 P43166 2/20 0.37
▸ CA9 Q16790 2/20 0.37
▸ CA14 Q9ULX7 2/20 0.37
▸ CYP4F2 P78329 1/20 0.36
▸ CYP4A11 Q02928 1/20 0.36
▸ PDE3B Q13370 1/20 0.36
▸ PDE3A Q14432 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852641 1.00 GABRA1 (0.42) GABRA1GABRB1GABRA3GABRB2ALDH1A1
SCHEMBL29852836 0.86 ABCB11 (0.38) GABRA1GABRB1GABRA3GABRB2ALDH1A1
SCHEMBL23218323 0.86 ABCB11 (0.38) GABRA1GABRB1GABRA3GABRB2ALDH1A1
SCHEMBL29853260 0.86 ALDH1A1 (0.42) GABRA1GABRB1GABRA3GABRB2ALDH1A1
SCHEMBL23218838 0.86 ALDH1A1 (0.42) GABRA1GABRB1GABRA3GABRB2ALDH1A1
SCHEMBL23219261 0.84 GABRA1 (0.36) GABRA1GABRB1GABRA3GABRB2ALDH1A1
SCHEMBL31615139 0.84 GABRA1 (0.36) GABRA1GABRB1GABRA3GABRB2ALDH1A1
SCHEMBL23218947 0.81 ALDH1A1 (0.45) GABRA1GABRB1GABRA3GABRB2ALDH1A1
SCHEMBL23218569 0.80 LMNA (0.46) GABRA1GABRB1GABRA3GABRB2ALDH1A1
SCHEMBL23218654 0.79 GABRA1 (0.45) GABRA1GABRB1GABRA3GABRB2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB GABRA1 3792/4885GABRB1 3695/4885GABRA3 3720/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB GABRA1 4487/4885GABRB1 4598/4885GABRA3 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.